ipamorelin peptide therapy in san francisco ca cjc-1295 ipamorelin peptide therapy Peptide

The International Journal of Developmental Biology, 62 (6-7-8), 491-505

(1998) described Ipamorelin as the first selective GH secretagogue raising GH with minimal cortisol or prolactin effect

Scientific Activity The CJC-1295 component engages a class B1 G-protein-coupled receptor and cyclic AMP signaling, while ipamorelin engages the ghrelin receptor through Gq, phospholipase C, and intracellular calcium pathways

The compound gently activates GH synthesis in the pituitary gland without affecting other hormones such as cortisol and prolactin

However, combining peptide therapy with a healthy diet and regular exercise often yields the best results

Mild headache : Occasionally reported in clinical studies, typically transient